Isotechnika Pharma (AUPH) Raised to “Hold” at BidaskClub

Isotechnika Pharma (NASDAQ:AUPH) (TSE:AUP) was upgraded by equities research analysts at BidaskClub from a “sell” rating to a “hold” rating in a report issued on Saturday.

A number of other research analysts also recently commented on the stock. Zacks Investment Research downgraded shares of Isotechnika Pharma from a “hold” rating to a “sell” rating in a research report on Wednesday. Seaport Global Securities reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Isotechnika Pharma in a research report on Friday, March 16th. Cantor Fitzgerald set a $16.00 price objective on shares of Isotechnika Pharma and gave the stock an “overweight” rating in a research report on Thursday, March 15th. Royal Bank of Canada assumed coverage on shares of Isotechnika Pharma in a research report on Thursday, February 8th. They issued an “outperform” rating and a $9.00 price objective on the stock. Finally, ValuEngine raised shares of Isotechnika Pharma from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. One research analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Isotechnika Pharma has an average rating of “Buy” and a consensus target price of $10.92.

NASDAQ AUPH opened at $5.44 on Friday. The stock has a market cap of $452.20, a price-to-earnings ratio of -5.91 and a beta of 2.26. Isotechnika Pharma has a one year low of $4.41 and a one year high of $8.19.



Isotechnika Pharma (NASDAQ:AUPH) (TSE:AUP) last posted its earnings results on Thursday, March 15th. The biotechnology company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10. The business had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.03 million. Isotechnika Pharma had a negative net margin of 16,855.24% and a negative return on equity of 17.54%. The company’s revenue for the quarter was up .0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.11) EPS. equities research analysts expect that Isotechnika Pharma will post -0.7 earnings per share for the current fiscal year.

Several institutional investors have recently modified their holdings of AUPH. Ameriprise Financial Inc. grew its position in shares of Isotechnika Pharma by 39.7% in the 3rd quarter. Ameriprise Financial Inc. now owns 211,569 shares of the biotechnology company’s stock worth $1,327,000 after buying an additional 60,101 shares during the last quarter. Wells Fargo & Company MN grew its position in shares of Isotechnika Pharma by 13,197.5% in the 3rd quarter. Wells Fargo & Company MN now owns 26,595 shares of the biotechnology company’s stock worth $166,000 after buying an additional 26,395 shares during the last quarter. Cutler Capital Management LLC grew its position in shares of Isotechnika Pharma by 25.0% in the 4th quarter. Cutler Capital Management LLC now owns 50,000 shares of the biotechnology company’s stock worth $226,000 after buying an additional 10,000 shares during the last quarter. Swiss National Bank purchased a new position in shares of Isotechnika Pharma in the 4th quarter worth approximately $421,000. Finally, BlackRock Inc. purchased a new position in shares of Isotechnika Pharma in the 4th quarter worth approximately $3,261,000. 28.50% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “Isotechnika Pharma (AUPH) Raised to “Hold” at BidaskClub” was originally posted by Dakota Financial News and is the property of of Dakota Financial News. If you are viewing this piece of content on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this piece of content can be viewed at https://dakotafinancialnews.com/2018/04/14/isotechnika-pharma-auph-raised-to-hold-at-bidaskclub.html.

Isotechnika Pharma Company Profile

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the development of a therapeutic drug to treat autoimmune diseases in Canada and internationally. The company is developing Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It has partnership agreements with Paladin Labs Inc and 3SBio, Inc The company was formerly known as Isotechnika Pharma Inc and changed its name to Aurinia Pharmaceuticals Inc in October 2013.

Analyst Recommendations for Isotechnika Pharma (NASDAQ:AUPH)

Receive News & Ratings for Isotechnika Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Isotechnika Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply